Diametric Capital’s Abeona Therapeutics ABEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.67M Buy
755,021
+143,501
+23% +$788K 0.49% 27
2026
Q1
$2.74M Sell
611,520
-82,901
-12% -$414K 0.71% 21
2025
Q4
$3.66M Buy
694,421
+521,220
+301% +$2.62M 0.98% 14
2025
Q3
$915K Buy
173,201
+34,838
+25% +$221K 0.34% 70
2025
Q2
$786K Buy
138,363
+119,609
+638% +$681K 0.42% 62
2025
Q1
$89.3K Buy
+18,754
New +$102K 0.11% 175

Other funds holding ABEO

Diametric Capital's ABEO Position: Q2 2026 in Review

Diametric Capital increased its Abeona Therapeutics (ABEO) stake by 23% in Q2 2026, buying an estimated $788K and bringing the position to 755,021 shares worth $4.67M. The position accounts for 0.49% of the portfolio, ranked #27.

Diametric Capital first reported a position in ABEO in Q1 2025 and has held it in 6 quarters since. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Diametric Capital held 755,021 shares of Abeona Therapeutics worth $4.67M as of Q2 2026.
  • Diametric Capital bought 143,501 Abeona Therapeutics shares in Q2 2026, an estimated $788K.
  • Abeona Therapeutics made up 0.49% of Diametric Capital's portfolio in Q2 2026, its #27 holding.
  • Diametric Capital first reported a position in Abeona Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.